Research at Oslo University Hospital basis for international drug development initiative between Norway and India
Kjetil Taskén (left) and Ivar Sjaastad
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.
The work has involved Birgitte Lygren (former postdoc), Ellen Østensen (PhD 2016), Ana Calejo (former postdoc and now researcher with UiO SPARK grant) in the Taskén group at UiO/OUH and has been done in collaboration with Professor Jo Klaveness at Institute of Pharmacy and Professor Ivar Sjaastad and Researcher Jan Magnus Aaronsen at Institute of Experimental Medical Research at Oslo University Hospital and in collaboration with Inven2, particularly Mohammed Amarzguioui and Kristin Sandereid, that have been involved in the technology and business development and led to the establishment of SERCA Pharmaceuticals AS.
SERCA Pharmaceuticals AS has won a 5-mill NOK Forny grant from RCN. The agreement with Cadila will take the project forward and provides a real chance to go into humans with planned phase 1 and 2 studies.
Inven2's most recent startup company, Serca Pharmaceuticals, signed a development agreement with Cadila Pharmaceuticals in New Delhi today. The signing was overseen by Prime Minister of Norway, Erna Solberg, during her official visit to India. Serca Pharmaceuticals is based on breakthrough science from Kjetil Taskéns Group at the University of Oslo. Read more
From major journals, first or last author from the Institute for Cancer Research
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
Rødland GE, Temelie M, Eek Mariampillai A, Hauge S, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG(2024) Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors Cells, 13(12) DOI 10.3390/cells13121058, PubMed 38920686
Kurganovs NJ, Engedal N(2024) To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics Front Pharmacol, 15, 1419806 DOI 10.3389/fphar.2024.1419806, PubMed 38910881
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl RH, Mazzeo P, Schmidt N, Koch R, Hallek MJ, Chebel A, Armisen Det al.(2024) Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses Blood(in press) DOI 10.1182/blood.2023022884, PubMed 38941598
Narod SA, Gronwald J, Karlan B, Moller P, Huzarski T, Tung N, Aeilts A, Eisen A, Randall Armel S, Singer CF, Foulkes WD, Neuhausen SL, Olopade O, Pal T, Fruscio R, Metcalfe K, Raj R, Jacobson M, Sun P, Lubinski J, Kotsopoulos J(2024) Incidence of Peritoneal Cancer Following Oophorectomy among BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst(in press) DOI 10.1093/jnci/djae151, PubMed 38937272